Rua Life Sciences Plc (RUA) 2006年年度报告「LSE」.pdf

1、Chairmans Statement Board of Directors and Advisors Report of The DirectorsCorporate Governance Report of The Remuneration CommitteeReport of The Independent Auditors Consolidated Profit and Loss Account Balance Sheets Consolidated Cashflow Statement Notes to the Financial Statements Notice of Annua

2、l General Meeting 01_06_07_10_12_15_16_17_18_19_30_CONTENTS/CHAIRMANS STATEMENT _FINANCIAL YEAR ENDED 31 MARCH 2006 SAW THE FIRST SIGNIFICANT INCOME FOR THE BIOMATERIALS-FOCUSED BUSINESS STRATEGY THAT HAS BEEN UNDERDEVELOPMENT SINCE 2003.RESULTS/Results to date are reflected in the summary financial

3、performance of the business:For the year ended 31 March 2006,the Companysturnover was 1,424,944,representing a more than10-fold increase over the previous years 136,958.Approximately 1.1million of the 2006 turnover resultedfrom the agreement signed with St.Jude Medical.Asthe substance of the transac

4、tion is that of a sale ofrights to the use of Elast-Eon in specified fields ofuse,this has been recognised as revenue in thesefinancial statements.Operating expenses for the yearwere 1,867,740,representing a reduction of almost15%over the previous year and being 26%less thanthe figure for 2004.The o

5、perating expenses included634,292 of development expenditure(2005:653,896)and amortisation of intangible fixed assets of99,491(2005:94,589).The Loss after Tax for theyear was 523,348,which compares with the loss for2005 of 1,867,390.The cash position as at 31 March 2006 was2,715,804,which compares w

6、ith 4,015,126 on thecorresponding day in 2005.However,the cash positionimproved significantly in April 2006 with the receipt ofthe US$2million(approximately 1.1million)initialpayment from St.Jude Medical in respect of theagreement concluded prior to the financial year end.Other tangible measures of